Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Nuclear Medicine Review. Central & Eastern Europe
|
August 12, 2020
99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair
Sara Shakeri, Parinaz Jahanpanah, Ghasemali Divband, et al.
Clinical Nuclear Medicine
|
August 12, 2025
Comparative Utility of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in Assessing Treatment Response in a Case of Metastatic Anal Melanoma With Brain Involvement
Ghasemali Divband, Masoume Chehrara, Nastaran Khodakarim, et al.
Clinical Nuclear Medicine
|
March 5, 2019
Whole-Body Blood Pool Metastatic Superscan (Bone Hunger Pattern)
Sara Shakeri, Somayeh Khosravi, Ghasemali Divband, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular
|
September 16, 2021
Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with <sup>177</sup>Lu-PSMA-617: A single center study
Soroush Zarehparvar Moghadam, Emran Askari, Ghasemali Divband, et al.
Clinical Nuclear Medicine
|
June 17, 2022
68 Ga-FAPI-46 and 18 F-FDG in Advanced Metastatic Pancreatic Cancer
Fatemeh Kaghazchi, Ghasemali Divband, Hamidreza Amini, et al.
Clinical Nuclear Medicine
|
June 10, 2025
177Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma
Hajar Albooyeh, Hamidreza Amini, Maryam Arefnia, et al.
Clinical Nuclear Medicine
|
July 1, 2022
68 Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression
Kamran Aryana, Reyhaneh Manafi-Farid, Hamidreza Amini, et al.
Nuclear Medicine Review. Central & Eastern Europe
|
July 18, 2022
Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE
Ghasemali Divband, Seyed Hootan Alavi, Zohre Adinehpour, et al.
Clinical Nuclear Medicine
|
January 12, 2026
Heterogeneous Response After [177Lu]Lu-FAPI-2286 Combination Therapy in Metastatic Breast Cancer
Ghasemali Divband, Masoume Chehrara, Nastaran Khodakarim, et al.
Asia Oceania Journal of Nuclear Medicine & Biology
|
June 16, 2023
Development and evaluation of <sup>89</sup>Zr-trastuzumab for clinical applications
Fatemeh Mohammadpour-Ghazi, Hassan Yousefnia, GhasemAli Divband, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Nuclear Medicine Review. Central & Eastern Europe
|
August 12, 2020
99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair
Sara Shakeri, Parinaz Jahanpanah, Ghasemali Divband, et al.
Clinical Nuclear Medicine
|
August 12, 2025
Comparative Utility of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in Assessing Treatment Response in a Case of Metastatic Anal Melanoma With Brain Involvement
Ghasemali Divband, Masoume Chehrara, Nastaran Khodakarim, et al.
Clinical Nuclear Medicine
|
March 5, 2019
Whole-Body Blood Pool Metastatic Superscan (Bone Hunger Pattern)
Sara Shakeri, Somayeh Khosravi, Ghasemali Divband, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular
|
September 16, 2021
Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with <sup>177</sup>Lu-PSMA-617: A single center study
Soroush Zarehparvar Moghadam, Emran Askari, Ghasemali Divband, et al.
Clinical Nuclear Medicine
|
June 17, 2022
68 Ga-FAPI-46 and 18 F-FDG in Advanced Metastatic Pancreatic Cancer
Fatemeh Kaghazchi, Ghasemali Divband, Hamidreza Amini, et al.
Clinical Nuclear Medicine
|
June 10, 2025
177Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma
Hajar Albooyeh, Hamidreza Amini, Maryam Arefnia, et al.
Clinical Nuclear Medicine
|
July 1, 2022
68 Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression
Kamran Aryana, Reyhaneh Manafi-Farid, Hamidreza Amini, et al.
Nuclear Medicine Review. Central & Eastern Europe
|
July 18, 2022
Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE
Ghasemali Divband, Seyed Hootan Alavi, Zohre Adinehpour, et al.
Clinical Nuclear Medicine
|
January 12, 2026
Heterogeneous Response After [177Lu]Lu-FAPI-2286 Combination Therapy in Metastatic Breast Cancer
Ghasemali Divband, Masoume Chehrara, Nastaran Khodakarim, et al.
Asia Oceania Journal of Nuclear Medicine & Biology
|
June 16, 2023
Development and evaluation of <sup>89</sup>Zr-trastuzumab for clinical applications
Fatemeh Mohammadpour-Ghazi, Hassan Yousefnia, GhasemAli Divband, et al.
Page
of 4